이 누리집은 대한민국 공식 전자정부 누리집입니다.
Biz News Korea(Eng)
Korean biosimilars expand footprint in Europe
- Collected
- 2016.07.26
- Distributed
- 2016.07.27
- Source
- Go Direct
The company reported sales $15 million in the second quarter, jumping 7.5 times from the first quarter when the biosimilar first became available in Europe.
Samsung Bioepis expects it will generate nearly 100 billion won ($88 million) in sales from Benepali alone this year. Samsung Bioepis initially produced the biosimilar at Biogen’s plant in Denmark, and was recently consigned to produce the drugs also from its facility in Korea to meet the growing demand.
Celltrion’s biosimilar Inflectra marketed by Pfizer in Europe since 2013 has been selling remarkably well. Its market share in Norway jumped to 93 percent at the end of April from a mere 9 percent in February of last year as the Norwegian government is actively recommending biosimilars to save its health budget.
Celltrion plans to take its biosimilar to other parts of the European continent. According to the pharmaceutical industry in Europe, Inflectra’s market share stood at 97 percent in Denmark, 88 percent in Finland and 33.5 percent in Sweden. It was 27 percent in the Netherlands, 11 percent in France and 14 percent in Germany.
Korean bioengineering companies were able to make a headway in Europe because they were able to gain license faster than others. They also carried out aggressive marketing strategy towards hospitals and governments in Europe.
By Lee Dong-in
[ⓒ Pulse by Maeil Business News Korea & mk.co.kr, All rights reserved]